Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Subscribe To Our Newsletter & Stay Updated
